The National Medical Products Administration (NMPA) of China approved the combination of Bestuzumab (generic name: injection of Vemurafenib) and Keytruda (generic name: injection of Pembrolizumab) for adult patients with locally advanced or metastatic urothelial carcinoma. The new combination therapy will provide an alternative for patients in China with locally advanced or metastatic urothelial carcinoma, replacing the standard platinum-based chemotherapy regimen that has been used for nearly 40 years, becoming a new treatment option.
NMPA批准备思复联合可瑞达用于治疗晚期膀胱癌
The NMPA approved the combination of Bestuzumab and Keytruda for the treatment of advanced bladder cancer.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
